Home » Stocks » DiaMedica Therapeutics

DiaMedica Therapeutics Inc. (DMAC)

Stock Price: $4.21 USD -0.11 (-2.55%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 78.89M
Revenue (ttm) n/a
Net Income (ttm) -9.83M
Shares Out 18.74M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $4.21
Previous Close $4.32
Change ($) -0.11
Change (%) -2.55%
Day's Open 4.30
Day's Range 4.20 - 4.46
Day's Volume 83,220
52-Week Range 1.87 - 8.80

More Stats

Market Cap 78.89M
Enterprise Value 67.19M
Earnings Date (est) Dec 7, 2020
Ex-Dividend Date n/a
Shares Outstanding 18.74M
Float 17.38M
EPS (basic) -0.77
EPS (diluted) -0.77
FCF / Share -0.49
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 22,236
Short Ratio 0.78
Short % of Float 0.13%
Beta 1.95
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 7.65
Revenue n/a
Operating Income -10.54M
Net Income -9.83M
Free Cash Flow -6.92M
Net Cash 11.70M
Net Cash / Share 0.62
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -51.93%
ROE -85.55%
ROIC -153.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(240.38% upside)
Current: $4.21
Target: 14.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit-0.50--
Operating Income-11.59-6.76-4.52-2.33
Net Income-10.65-5.73-4.26-2.22
Shares Outstanding11.997.745.944.74
Earnings Per Share-0.89-0.74-0.72-0.47
Operating Cash Flow-9.10-5.70-3.90-2.99
Capital Expenditures0.01-0.05-0.02-0.01
Free Cash Flow-9.09-5.75-3.92-2.99
Cash & Equivalents7.9716.821.351.74
Total Debt0.180.02--
Net Cash / Debt7.7916.801.351.74
Book Value7.6217.030.801.11
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name DiaMedica Therapeutics Inc.
Country United States
Employees 8
CEO Rick John Pauls

Stock Information

Ticker Symbol DMAC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: DMAC


DiaMedica Therapeutics, a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company also develops DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was founded in 2000 and is headquartered in Minneapolis, Minnesota.